| Identification | Back Directory | [Name]
LIGUSTRAZOINEHYDROCHLORIDE | [CAS]
76494-51-4 | [Synonyms]
Tetrapyrazine HCl
Tetramethylpyrazine HCl
LIGUSTRAZOINEHYDROCHLORIDE
Chuanxiongzine Hydrochlorid
Tetramethylphrazine USP/EP/BP
2,3,5,6-Tetramethylpyrazine hydrochloride
Tetramethylpyrazine Hydrochloride USP/EP/BP
Chuanxiongzine Hydrochloride, TetraMethylpyrazine hydrochloride | [EINECS(EC#)]
1592732-453-0 | [Molecular Formula]
C8H12N2.ClH | [MDL Number]
MFCD01109103 | [MOL File]
76494-51-4.mol | [Molecular Weight]
172.658 |
| Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml; PBS (pH 7.2): 10 mg/ml | [form ]
powder | [color ]
White |
| Hazard Information | Back Directory | [Description]
Ligustrazine Hydrochloride, its main function is to inhibit platelet aggregation and prevent thrombosis. At the same time, it can resist vascular damage caused by serotonin and bradykinin, increase capillary resistance, reduce capillary permeability, and prevent edema caused by increased vascular permeability. Clinically, it is mainly used for occlusive syndrome, thrombophlebitis, capillary bleeding, etc. The market demand for this product is large. | [Chemical Properties]
White crystalline powder, soluble in methanol, ethanol, DMSO and other organic solvents, derived from the dried root of Ligusticum chuanxiong hort. | [Uses]
Ligustrazine Hydrochloride has the effect of antiplatelet coagulation, dilation of small arteries, treatment of occlusive cerebrovascular disease. | [Application]
Ligustrazine Hydrochloride can be used to treat cerebral insufficiency, cerebral thrombosis, cerebral embolism and other ischemic vascular diseases, such as coronary atherosclerotic heart disease, vasculitis, etc. When the patient is in the acute stage of the disease, intravenous drip is generally used. | [target]
IL Receptor | NOS | NO | TGF-β/Smad | TXA2 - PGI2 | VEGFR |
|
|